These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2841741)

  • 21. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
    Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
    Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
    Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.
    Guillet B; Simon N; Sampol JJ; Lorec-Penet AM; Portugal H; Berland Y; Dussol B; Brunet P
    Nephrol Dial Transplant; 2003 Nov; 18(11):2348-53. PubMed ID: 14551364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin.
    Nurmohamed MT; ten Cate J; Stevens P; Hoek JA; Lins RL; ten Cate JW
    ASAIO Trans; 1991; 37(3):M459-61. PubMed ID: 1661121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Krueger K; Schmutz A; Zieger B; Kalbhenn J
    Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
    Nowak G; Bucha E; Brauns I; Czerwinski R
    Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A low molecular weight heparin in hemodialysis.
    Maurin N; Kierdorf H
    Klin Wochenschr; 1988 Mar; 66(6):246-9. PubMed ID: 2835544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of enoxaparine for anticoagulation in extracorporeal circulation in hemodialysis at high risk for hemorrhage].
    Dechelette E; Pouzol P; Jurkovitz C; Kuentz F; Polack B; Cuzin E; Woler M
    J Mal Vasc; 1987; 12 Suppl B():105-7. PubMed ID: 2834479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
    Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE
    Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
    Chan KE; Thadhani RI; Maddux FW
    Kidney Int; 2013 Sep; 84(3):555-61. PubMed ID: 23677243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of anticoagulation on blood membrane interactions during hemodialysis.
    Hofbauer R; Moser D; Frass M; Oberbauer R; Kaye AD; Wagner O; Kapiotis S; Druml W
    Kidney Int; 1999 Oct; 56(4):1578-83. PubMed ID: 10504511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
    Klingel R; Schaefer M; Schwarting A; Himmelsbach F; Altes U; Uhlenbusch-Körwer I; Hafner G
    Nephrol Dial Transplant; 2004 Jan; 19(1):164-70. PubMed ID: 14671052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Are low-molecular-weight heparins safe in patients with chronic kidney disease?].
    Vega S J; Martínez R G; Goecke S H
    Rev Med Chil; 2010 Apr; 138(4):487-95. PubMed ID: 20668799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis.
    Colì L; Donati G; Cianciolo G; Raimondi C; Comai G; Panicali L; Nastasi V; Cannarile DC; Gozzetti F; Piccari M; Stefoni S
    J Vasc Access; 2006; 7(3):118-22. PubMed ID: 17019663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin.
    Sarris E; Tsele E; Bagiatoudi G; Salpigidis K; Stavrianaki D; Kaklamanis L; Siakotos M
    Am J Kidney Dis; 2003 May; 41(5):E15. PubMed ID: 12778433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage.
    Hafner G; Klingel R; Wandel E; Ehrenthal W; Konheiser U; Lotz J; Köhler H; Prellwitz W
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):221-6. PubMed ID: 8054454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed elimination of enoxaparin in patients with chronic renal insufficiency.
    Cadroy Y; Pourrat J; Baladre MF; Saivin S; Houin G; Montastruc JL; Vernier I; Boneu B
    Thromb Res; 1991 Aug; 63(3):385-90. PubMed ID: 1659748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.